Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study

Table 1 Characteristics of HCV patients studied.

	Non-responders (n = 22)	Relapsers (n = 16)	Sustained responders (n = 19)
Sex (M/F)	15/7	10/6	13/6
Age (Mean/range)	48±15	50±10	37±13
Disease duration (yr)	2.4±2.1	2.9±3	2.5±2.4
Source of HCV Infection
Transfusion before 1990	8	4	4
Iv drug abuse	3	3	6
Multiple hospitalizations	3	0	0
Multiple sexual partners	0	1	2
Unknown	8	8	7
Genotype
1a/1b	11	8	8
2a/c	2	2	0
3a	4	4	7
4	4	1	2
Undefined	1	1	2
Viral load
>2.106 copies/mL	9	10	10
≤2.106 copies/mL	13	6	9
Histologic data (Yes/No)	14/8	11/5	10/9
Minimal/mild inflammation	12	6	9
Moderate/severe inflammation	2	5	1
None/mild/moderate fibrosis	10	5	10
Severe fibrosis or cirrhosis	4	6	0
HBV and/or HIV co-infection	0	0	0